文献速递肝病

COVID-19大流行期间饮酒量增加对酒精相关性肝病的影响:一项模型研究

Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study.
PubMed 文献 · Hepatology · 2022-01-24

该模型研究基于美国1920至2012年出生人群,模拟COVID-19期间饮酒量增加对酒精相关性肝病(ALD)及死亡的影响。作者认为短期饮酒增加可显著升高长期ALD相关发病率与死亡率。

要点

  • COVID-19期间饮酒量增加预计在2020至2040年间导致8000例额外ALD相关死亡。
  • 同期预计新增18700例失代偿期肝硬化和1000例肝细胞癌。
  • 2020至2023年间预计额外增加100例死亡和2800例失代偿期肝硬化。

核心结论

  • COVID-19大流行期间短期饮酒量增加可显著升高长期ALD相关发病率与死亡率。
  • 研究结果强调个人和政策制定者需做出知情决策以减轻美国高风险饮酒的影响。

研究设计与样本

  • 扩展既往验证的微模拟模型,估计COVID-19期间饮酒增加对美国1920至2012年出生个体的短期和长期影响。
  • 使用2020年2月至11月全国代表性样本饮酒变化调查数据模拟当前饮酒模式(现状)的结局。
  • 与无COVID-19且饮酒模式不变的 counterfactual 场景进行比较。

主要发现

  • COVID-19期间一年饮酒量增加预计导致8000例(95%不确定性区间[UI] 7500-8600)额外ALD相关死亡。
  • 预计新增18700例(95% UI 17600-19900)失代偿期肝硬化和1000例(95% UI 1000-1100)肝细胞癌。
  • 2020至2023年间,COVID-19相关饮酒变化将导致100例(100-200)额外死亡和2800例(2700-2900)额外失代偿期肝硬化。
  • 饮酒量持续增加超过1年可能导致额外的发病率与死亡率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Alcohol consumption increased during the COVID-19 pandemic in 2020 in the United States. We projected the effect of increased alcohol consumption on alcohol-associated liver disease (ALD) and mortality. APPROACH AND RESULTS: We extended a previously validated microsimulation model that estimated the short- and long-term effect of increased drinking during the COVID-19 pandemic in individuals in the United States born between 1920 and 2012. We modeled short- and long-term outcomes of current drinking patterns during COVID-19 (status quo) using survey data of changes in alcohol consumption in a nationally representative sample between February and November 2020. We compared these outcomes with a counterfactual scenario wherein no COVID-19 occurs and drinking patterns do not change. One-year increase in alcohol consumption during the COVID-19 pandemic is estimated to result in 8000 (95% uncertainty interval [UI], 7500-8600) additional ALD-related deaths, 18,700 (95% UI, 17,600-19,900) cases of decompensated cirrhosis, and 1000 (95% UI, 1000-1100) cases of HCC, and 8.9 million disability-adjusted life years between 2020 and 2040. Between 2020 and 2023, alcohol consumption changes due to COVID-19 will lead to 100 (100-200) additional deaths and 2800 (2700-2900) additional decompensated cirrhosis cases. A sustained increase in alcohol consumption for more than 1 year could result in additional morbidity and mortality. CONCLUSIONS: A short-term increase in alcohol consumption during the COVID-19 pandemic can substantially increase long-term ALD-related morbidity and mortality. Our findings highlight the need for individuals and policymakers to make informed decisions to mitigate the impact of high-risk alcohol drinking in the United States.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Julien J, Ayer T, Tapper EB, et al. Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study. Hepatology. 2022. PMID: 34878683. doi:10.1002/hep.32272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。